• 摘要: 自2019年底以来,新型冠状病毒(新冠病毒)感染大流行已席卷全球。虽然目前的新冠病毒变异株的致病性和毒力已较原始株有所下降,大多数患者预后良好,但实体器官移植(SOT)受者为新冠病毒感染脆弱人群,即使全程接种新冠病毒疫苗,SOT受者感染新冠病毒的住院或死亡风险依然较高。SOT受者新冠病毒感染后其临床表现、诊断和治疗均与普通人群存在很大的特殊性,需要高度关注。目前尚缺乏针对SOT受者可供参考的新冠病毒感染诊疗领域的指南或共识。因此,参考《新型冠状病毒感染诊疗方案(试行第十版)》及国内外文献,编写团队撰写了《实体器官移植受者新型冠状病毒感染诊疗专家共识(2023年版)》。本共识基于国内外新冠病毒感染的循证医学证据,并经过专家多次研讨达成一致意见后撰写成文,形成21条推荐意见,为SOT受者感染新冠病毒的诊疗提供参考。

     

    Abstract: Since the end of 2019, the SARS-CoV-2 infection pandemic has swept the world. Although the current SARS-CoV-2 mutants have decreased in pathogenicity and virulence compared with the original strains, and most patients have a good prognosis, the solid organ transplant (SOT) recipients are vulnerable to SARS-CoV-2. And even with vaccination, the risk of hospitalization or death is still high in SOT recipients infected with SARS-CoV-2. What's more, the clinical manifestations, diagnosis and treatment strategy of SOT recipients infected with SARS-CoV-2 has its unique features, which needs high attention. At present, there is a lack of guidelines or consensus in the diagnosis and treatment field of SARS-CoV-2 for such a large number of SOT recipients. Therefore, referring to the "Diagnosis and treatment regimen for SARS-CoV-2 infection (Trial Version 10)" and global published literature, the writing team wrote the "Expert consensus on diagnosis and treatment of SARS-CoV-2 infection in solid organ transplantation recipients (2023 edition)". This consensus was evidence-based written and reached by experts after multiple rounds of discussions, forming 21 recommendations, providing reference for the diagnosis and treatment of SOT recipients infected with SARS-CoV-2.

     

/

返回文章
返回